Items where authors include "Coleman, R.E."

Article

Rugo, H.S. orcid.org/0000-0001-6710-4814, Van Poznak, C.H. orcid.org/0000-0001-5523-6908, Neven, P. orcid.org/0000-0002-1434-9460 et al. (12 more authors) (2024) Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Research and Treatment, 204 (2). pp. 249-259. ISSN 0167-6806

Goyal, A., Mann, G.B., Fallowfield, L. et al. (28 more authors) (2021) POSNOC—POsitive Sentinel NOde : adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy : a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open, 11 (12). e054365.

Brown, J.E., Handforth, C., Compston, J.E. et al. (13 more authors) (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 25. 100311. ISSN 2212-1374

Robertson, J.F.R., Coleman, R.E. orcid.org/0000-0002-4275-1043, Cheung, K.-L. et al. (21 more authors) (2020) Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical Cancer Research, 26 (7). pp. 1574-1585. ISSN 1078-0432

Danson, S. orcid.org/0000-0002-3593-2890, Mulvey, M.R., Turner, L. et al. (6 more authors) (2019) An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. Journal of Bone Oncology, 19. 100261. ISSN 2212-1374

Walsh, J.S. orcid.org/0000-0002-7122-2650, Marshall, H., Smith, I.L. et al. (9 more authors) (2019) Testosterone replacement in young male cancer survivors : a 6-month double-blind randomised placebo-controlled trial. PLOS Medicine, 16 (11). e1002960. ISSN 1549-1277

Sestak, I., Blake, G.M., Patel, R. et al. (3 more authors) (2019) Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone, 124. pp. 83-88. ISSN 8756-3282

Tulotta, C., Lefley, D.V., Freeman, K. et al. (16 more authors) (2019) Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment. Clinical Cancer Research, 25 (9). pp. 2769-2782. ISSN 1078-0432

Westbrook, J.A., Wood, S.L., Cairns, D.A. et al. (14 more authors) (2019) Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of Pathology, 247 (3). pp. 381-391. ISSN 0022-3417

Coleman, R.E., Collinson, M., Gregory, W. et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). JOURNAL OF BONE ONCOLOGY, 13. pp. 123-135. ISSN 2212-1374

Handforth, C. orcid.org/0000-0001-5171-4917, Burkinshaw, R., Freeman, J. et al. (4 more authors) (2018) Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer.

Ubellacker, J.M., Baryawno, N., Severe, N. et al. (13 more authors) (2018) Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer. Cancer Research . ISSN 0008-5472

Logothetis, C., Morris, M.J., Den, R. et al. (1 more author) (2018) Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer and Metastasis Reviews, 37 (1). pp. 189-196. ISSN 0167-7659

Wilson, C., Hinsley, S., Marshall, H. et al. (4 more authors) (2017) Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study. Journal of Bone Oncology, 9. pp. 48-54. ISSN 2212-1374

Sartor, O., Coleman, R.E. orcid.org/0000-0002-4275-1043, Nilsson, S. et al. (11 more authors) (2017) An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Annals of Oncology, 28 (5). pp. 1090-1097. ISSN 0923-7534

Hadji, P., Aapro, M.S., Body, J-J. et al. (18 more authors) (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. Journal of Bone Oncology, 7. pp. 1-12. ISSN 2212-1374

Parker, C., Zhan, L., Cislo, P. et al. (6 more authors) (2017) Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. European Journal of Cancer, 71. C. pp. 1-6. ISSN 0959-8049

Parker, C., Finkelstein, S.E., Michalski, J.M. et al. (9 more authors) (2016) Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology, 70 (5). pp. 875-883. ISSN 0302-2838

Vogelzang, N.J., Coleman, R.E. orcid.org/0000-0002-4275-1043, Michalski, J.M. et al. (8 more authors) (2016) Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clinical Genitourinary Cancer. ISSN 1558-7673

Sartor, O., Hoskin, P., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (6 more authors) (2016) Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate, 76 (10). pp. 905-916. ISSN 0270-4137

Nilsson, S., Cislo, P., Sartor, O. et al. (7 more authors) (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Annals of Oncology, 27 (5). pp. 868-874. ISSN 0923-7534

Wilson, C., Gossiel, F., Leonard, R. et al. (4 more authors) (2016) Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. Journal of Bone Oncology, 5 (1). pp. 43-49. ISSN 2212-1374

Forbes, J.F., Sestak, I., Howell, A. et al. (13 more authors) (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet, 387 (10021). pp. 866-873. ISSN 0140-6736

Yardley, D.A., Brufsky, A., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (10 more authors) (2016) Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015). TRIALS, 17. p. 63. ISSN 1745-6215

Gregory, W.M., Twelves, C.J., Bell, R. et al. (4 more authors) (2016) Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Research and Treatment, 155 (2). pp. 303-311. ISSN 0167-6806

Westbrook, J.A., Cairns, D.A., Peng, J. et al. (10 more authors) (2016) CAPG and gipc1: Breast cancer biomarkers for bone metastasis development and treatment. Journal of the National Cancer Institute, 108 (4). ISSN 0027-8874

Holen, I. orcid.org/0000-0002-8759-6913, Lefley, D.V., Francis, S.E. et al. (4 more authors) (2016) IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget, 7. pp. 75571-75584. ISSN 1949-2553

Yardley, D.A., Brufsky, A., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (10 more authors) (2015) Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 16. 575. ISSN 1745-6215

Talari, A.C.S., Evans, C.A., Holen, I. et al. (2 more authors) (2015) Raman spectroscopic analysis differentiates between breast cancer cell lines. Journal of Raman Spectroscopy, 46 (5). 421 - 427. ISSN 0377-0486

Wilson, C., Ottewell, P., Coleman, R.E. et al. (1 more author) (2015) The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway. BMC Cancer, 15. 55. ISSN 1471-2407

Smith, M.R., Coleman, R.E. orcid.org/0000-0002-4275-1043, Klotz, L. et al. (9 more authors) (2015) Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Annals of Oncology, 26 (2). pp. 368-374. ISSN 0923-7534

Saxton, J.M., Scott, E.J., Daley, A.J. et al. (5 more authors) (2014) Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. Breast Cancer Research, 16 (2). R39. ISSN 1465-542X

Coleman, R.E. orcid.org/0000-0002-4275-1043, Lipton, A., Costa, L. et al. (9 more authors) (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2 (2). pp. 70-76. ISSN 2212-1366

Lester, J.E., Dodwell, D., Brown, J.E. et al. (6 more authors) (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. Journal of Bone Oncology, 1 (2). pp. 57-62. ISSN 2212-1374

Brown, H.K., Ottewell, P.D., Evans, C.A. et al. (2 more authors) (2012) A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology, 1. pp. 47-56. ISSN 2212-1374

Walkington, L., Webster, J., Hancock, B.W. et al. (2 more authors) (2011) Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease. British Journal of Cancer, 104 (11). pp. 1665-1669. ISSN 0007-0920

Brown, H.K., Ottewell, P.D., Coleman, R.E. et al. (1 more author) (2011) The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. Journal of Cellular and Molecular Medicine, 15 (3). 501 - 513. ISSN 1582-1838

Holen, I. orcid.org/0000-0002-8759-6913 and Coleman, R.E. orcid.org/0000-0002-4275-1043 (2010) Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Research, 12. 214. ISSN 1465-5411

Coleman, R.E. orcid.org/0000-0002-4275-1043, Lipton, A., Roodman, G.D. et al. (11 more authors) (2010) Metastasis and bone loss: Advancing treatment and prevention. Cancer Treatment Reviews, 36 (8). pp. 615-620. ISSN 0305-7372

Coleman, R.E. orcid.org/0000-0002-4275-1043, Winter, M.C., Cameron, D. et al. (11 more authors) (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. British Journal of Cancer, 102 (7). pp. 1099-1105. ISSN 0007-0920

Neville-Webbe, H.L., Coleman, R.E. orcid.org/0000-0002-4275-1043 and Holen, I. orcid.org/0000-0002-8759-6913 (2010) Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. British Journal of Cancer, 102. pp. 1010-1017. ISSN 0007-0920

Greenfield, D.M., Absolom, K., Eiser, C. et al. (6 more authors) (2009) Follow-up care for cancer survivors: the views of clinicians. British Journal of Cancer, 101 (4). pp. 568-574. ISSN 0007-0920

Absolom, K., Eiser, C., Michel, G. et al. (6 more authors) (2009) Follow-up care for cancer survivors: views of the younger adult. British Journal of Cancer, 101 (4). pp. 561-567. ISSN 0007-0920

Major, P.P., Cook, R.J., Lipton, A. et al. (3 more authors) (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer, 9. 272.

Coleman, R.E. (2009) Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor. Breast Cancer Research, 11 (Suppl ). S16. ISSN 1465-5411

Wardley, A.M., Hiller, L., Howard, H.C. et al. (8 more authors) (2008) tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, 99 (4). pp. 597-603. ISSN 0007-0920

Coleman, R.E. orcid.org/0000-0002-4275-1043 (2008) Risks and benefits of bisphosphonates. British Journal of Cancer, 98 (11). pp. 1736-1740. ISSN 0007-0920

Greenfield, D.M., Wright, J., Brown, J.E. et al. (6 more authors) (2006) High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening. British Journal of Cancer, 94. pp. 469-472. ISSN 0007-0920

Lester, J.E., Dodwell, D., Horsman, J.M. orcid.org/0000-0002-6454-642X et al. (2 more authors) (2006) Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. British Journal of Cancer, 94 (1). pp. 30-35. ISSN 0007-0920

Hall, G.D., Brown, J.M., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (8 more authors) (2004) Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. British Journal of Cancer, 91 (4). pp. 621-626. ISSN 0007-0920

Khan, F., Everard, J., Ahmed, S. et al. (3 more authors) (2003) Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. British Journal of Cancer , 89 (12). pp. 2197-2201. ISSN 0007-0920

Brown, J.E., Thomson, C.S., Ellis, S.P. et al. (3 more authors) (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. British Journal of Cancer, 89 (11). pp. 2031-2037. ISSN 0007-0920

Ashford, R.U., McCloskey, E.V. orcid.org/0000-0003-0177-8140, Purohit, O.P. et al. (3 more authors) (2002) Ten-year follow-up of a patient with metastatic Ewing's sarcoma of the pelvis. Sarcoma, 6. 529712. ISSN 1357-714X

Jagdev, S.P., Coleman, R.E. orcid.org/0000-0002-4275-1043, Shipman, C.M. et al. (2 more authors) (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. British Journal of Cancer, 84 (8). pp. 1126-1134. ISSN 0007-0920

Dobson, L.S. , Lorigan, P.C., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (1 more author) (2000) Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. British Journal of Cancer, 82 (9). pp. 1547-1552. ISSN 0007-0920

Gillespie, A.M., Liyim, D., Goepel, J.R. et al. (2 more authors) (2000) Placental site trophoblastic tumour : a rare but potentially curable cancer. British Journal of Cancer, 82 (6). pp. 1186-1190. ISSN 0007-0920

Garnero, P., Buchs, N., Zekri, J. et al. (3 more authors) (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. British Journal of Cancer, 82 (4). pp. 858-864. ISSN 0007-0920

Sharma, S., Jagdev, S., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (2 more authors) (1999) Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. British Journal of Cancer, 81 (6). pp. 1037-1041. ISSN 0007-0920

Gillespie, A.M., Siddiqui, N., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (1 more author) (1999) Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role? British Journal of Cancer, 79 (7-8). pp. 1270-1272. ISSN 0007-0920

Dobson, L.S., Gillespie, A.M., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (1 more author) (1999) The presentation and management of post-partum choriocarcinoma. British Journal of Cancer, 79 (9-10). pp. 1531-1533. ISSN 0007-0920

Adams, M., Calvert, A.H., Carmichael, J. et al. (20 more authors) (1998) Chemotherapy for ovarian cancer - a consensus statement on standard practice. British Journal of Cancer, 78 (11). pp. 1404-1406. ISSN 0007-0920

Gillespie, A.M., Rodgers, S., Wilson, A.P. et al. (4 more authors) (1998) MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. British Journal of Cancer, 78 (6). pp. 816-821. ISSN 0007-0920

Coleman, R.E. orcid.org/0000-0002-4275-1043, Smith, P. and Rubens, R.D. (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. British Journal of Cancer, 77 (2). pp. 336-340. ISSN 0007-0920

Purohit, O.P., Radstone, C.R., Anthony, C. et al. (2 more authors) (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. British Journal of Cancer, 72 (5). pp. 1289-1293. ISSN 0007-0920

Purohit, O.P., Anthony, C., Radstone, C.R. et al. (2 more authors) (1994) High-dose intravenous pamidronate for metastatic bone pain. British Journal of Cancer, 70 (3). pp. 554-558. ISSN 0007-0920

O'Rourke, N.P., McCloskey, E.V., Rosini, S. et al. (2 more authors) (1994) Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). British Journal of Cancer, 69 (5). pp. 914-917. ISSN 0007-0920

Coleman, R.E. orcid.org/0000-0002-4275-1043, Houston, S., James, I. et al. (4 more authors) (1992) Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. British Journal of Cancer, 65 (5). pp. 766-768. ISSN 0007-0920

Twelves, C.J., O'Reilly, S.M., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (2 more authors) (1989) Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. British Journal of Cancer, 60 (6). pp. 938-941. ISSN 0007-0920

Rubens, R.D., Tinson, C.L., Coleman, R.E. orcid.org/0000-0002-4275-1043 et al. (4 more authors) (1988) Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. British Journal of Cancer, 58 (5). pp. 626-630. ISSN 0007-0920

Coleman, R.E. orcid.org/0000-0002-4275-1043, Whitaker, K.B., Moss, D.W. et al. (3 more authors) (1988) Biochemical prediction of response of bone metastases to treatment. British Journal of Cancer, 58 (2). pp. 205-210. ISSN 0007-0920

Coleman, R.E. orcid.org/0000-0002-4275-1043 and Rubens, R.D. (1987) 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. British Journal of Cancer, 56 (4). pp. 465-469. ISSN 0007-0920

Coleman, R.E. orcid.org/0000-0002-4275-1043 and Rubens, R.D. (1987) The clinical course of bone metastases from breast cancer. British Journal of Cancer, 55 (1). pp. 61-66. ISSN 0007-0920

Monograph

Beard, S.M., Coleman, R.E., Radford, J. et al. (1 more author) (1998) Supplementary Document: The Use of Paclitaxel in the First Line Treatment of Ovarian Cancer. Other. Guidance Note for Purchasers (98/10). Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield , Sheffield. ISSN 1900733269

Conference or Workshop Item

Ottewell, P.D., Lefley, D.V., Coleman, R.E. et al. (1 more author) (2008) Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. In: Breast Cancer Research 2008, 13 May 2008, London, UK.

Lefley, D.V., Holen, I., Coleman, R.E. et al. (1 more author) (2008) Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. In: Breast Cancer Research 2008, May 2008, London, UK.

Holen, I., Neville-Webbe, H. and Coleman, R.E. (2006) Benefits of combined treatments using antiresorptive agents and cytotoxic drugs. In: Breast cancer research: the past and the future, 1 November 2006, London, UK.

Michailidou, M., Brown, N., Coleman, R.E. et al. (1 more author) (2006) Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro. In: Breast cancer research: the past and the future, 1 November 2006, London, UK.

Ottewell, P.D., Jones, M., Coleman, R.E. et al. (1 more author) (2006) Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo. In: Breast cancer research: the past and the future, 1 November 2006, London, UK.